News Releases

Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.

Month Year

Mar 7, 2022

Astellas Announces Topline Results from Long-Term Phase 3 Safety Study of Fezolinetant which Inform Future Regulatory Filings for the Treatment of Vasomotor Symptoms Associated with Menopause
Feb 28, 2022

Astellas and Seagen Announce CHMP Confirms Positive Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
Feb 14, 2022

Astellas and Seagen Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy

- Late-breaking data from Cohort H of EV-103 trial to be presented at the 2022 ASCO Genitourinary Cancers Symposium -
Feb 7, 2022

Astellas Announces Positive Safety Data from the FORTIS Study of AT845 in Adults with Late-Onset Pompe Disease

- Data presented at the 18th Annual WORLDSymposiumTM 2022 -
Dec 17, 2021

Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer

- If approved, PADCEV would be the first medicine for patients in the EU who have received prior platinum-based chemotherapy and a PD-1/L1 inhibitor -
Dec 14, 2021

Astellas and MBC BioLabs Announce Future Innovator Prize Winners - Helping Biotech Start-ups Accelerate Early Research Efforts

- Vcreate and Weatherwax Biotechnologies win a year of access to life-science incubator in San Francisco, CA and to Astellas expertise to further their research -
Dec 1, 2021

Astellas and Dyno Therapeutics Announce Research Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle

- Dyno receives $18 million upfront and is eligible for milestone and royalty payments potentially exceeding $1.6 billion -
Dec 1, 2021

Astellas to Present Research on FLT3 Mutation-Positive Acute Myeloid Leukemia - from Diagnosis to Relapse - at 2021 American Society of Hematology Annual Meeting

- Four AML oral presentations are among highest number of Astellas-sponsored ASH abstracts to date
Nov 17, 2021

The Astellas Global Health Foundation provides $1.85 million in funding to five organizations focused on improving health and COVID-19 recovery efforts for more than four million people in low-income communities

New grants will support needed education, training and community resilience in five countries
- Photos 1
Nov 3, 2021

Astellas and LabCentral Announce Future Innovator Prize Winners - Helping Emerging Biotechs Accelerate Growth of Innovative Science

- Thymmune Therapeutics and M13 Therapeutics win a year of access to life-science incubator in Cambridge, MA and access to Astellas expertise to further their research -

Show per page

Statements

Careers

Stay Connected

Get only the email alerts you want.

Media Contacts

For media inquiries and reporter requests, please click here to fill out a request form.

Our communications team will respond to verified media requests within 24-48 hours as appropriate.

If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.

Download Fact Sheet

Sustainability

Investors

Explore U.S. Products

News Releases

You are now leaving XTANDI.com

You are now leaving newsroom.astellas.com.